Publications by authors named "Mutlu Dogan"

Claim this Profile
R
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.
Tuğba Akın Telli, Ali Murat Tatlı, Özkan Alan, Gülsema Yıldıran Keskin, Nuri Karadurmuş

Clin Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study.
İlknur Deliktaş Onur, Mutlu Doğan, Mehmet Akif Öztürk, Taha Koray Sahin, Murat Kiracı

Curr Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group.
Salih Tunbekici, Gokhan Sahin, Sercan Ön, Ahmet Oruc, Melek Karakurt Eryılmaz, Mutlu Dogan

Int J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a.
Atilla Soran, Berk Göktepe, Berkay Demirors, Ozgur Aytac, Serdar Ozbas, Lutfi Dogan, Mutlu Dogan

Curr Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast Cancer.
Alper Turkel, Ece Baydar, Rümeysa Çolak, Ahmet Emin Öztürk, Teoman Şakalar, Mutlu Dogan

In Vivo· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Albumin-bilirubin (ALBI) and Platelet-ALBI (PALBI) Grades: Novel Prognostic Factors for Cholangiocellular Carcinoma.
Ergin Aydemir, Funda Yilmaz, Alper Türkel, Öztürk Ateş, Mutlu Doğan

In Vivo· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.
Seda Kahraman, Enes Erul, Ozge Gumusay, Deniz Can Guven, Sercan Aksoy, Ozlem Dogan, Atike Pinar Erdogan, Mutlu Dogan

Clin Breast Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unilateral facial nerve paralysis following prolonged weekly paclitaxel therapy: a rare case of cranial neurotoxicity with diagnostic challenges.
Ergin Aydemir, Alper Türkel, Kübra Okur, Taylan Altıparmak, Mutlu Doğan

J Chemother· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Pre-Treatment" and "Post-Treatment" Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?
Serkan Yaşar, Ahmet Kadıoğlu, Arif Akyildiz, Nadiye Sever, Mehmet Emin Büyükbayram, Mutlu Dogan

Medicina (Kaunas)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.
Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Aşık

Sci Rep· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Comparison of FLOT and DCF Regimens as Perioperative Treatment for Gastric Cancer.
Gökhan Uçar, Serhat Sekmek, İrfan Karahan, Yakup Ergün, Özlem Aydın İsak

Oncology· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03.
Neslihan Cabioglu, Hasan Karanlik, Abdullah Igci, Mahmut Muslumanoglu, Mehmet Ali Gulcelik, Lutfi Dogan, Mutlu Dogan

Ann Surg Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mediating effect of intrusive rumination on the relationship between illness uncertainty and fear of cancer recurrence in breast cancer survivors.
Alper Türkel, Nur Nihal Türkel, Ahmet Kadıoğlu, Mutlu Doğan, İrem Ekmekçi Ertek

BMC Womens Health· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.
Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Aşık

Sci Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors in non-metastatic HER2 'low' and HER2 'negative' breast cancer: single institute experience.
Alper Türkel, Mutlu Doğan, Elif Sertesen, Cengiz Karaçin, Sultan Çiğdem Irkkan

Wien Klin Wochenschr· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher TP53 somatic mutation prevalence from liquid biopsy analysis in ever smoker non-small-cell lung cancer patients.
Haktan Bağış Erdem, Mustafa Tarık Alay, Zeynep Özdemir, Ezgi Çevik, Öztürk Ateş

Mutat Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.
Seda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, Sema Sezgin Goksu, Akin Ozturk, Tolga Dogan, Mutlu Dogan, Izzet Dogan

Sci Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer.
Cengiz Karacin, Veli Sunar, Zuhat Urakci, Ali Yilmaz, Murat Ayhan, Mutlu Dogan, Dogan Uncu

Future Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic and Functional Impact of Sprouty 2 Expression in Non-small Cell Lung Cancer.
Yusuf Acikgoz, Fatma Unal Yildirim, Selin Akturk Esen, Gokhan Ucar, Yakup Ergun, Mutlu Dogan, Dogan Uncu

Am J Clin Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Zeynep Özdemir, Ezgi Çevik, Ömür Berna Çakmak Öksüzoğlu, Mutlu Doğan, Öztürk Ateş

Mutat Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis.
Yakup Ergun, Mutlu Dogan, Gokhan Ucar, Pınar Karacin, Cengiz Karacin

Expert Opin Pharmacother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simple and easily accessible prognostic markers in ewing sarcoma; neutrophil-lymphocyte ratio, neutrophil-platelet score and systemic-inflammation index.
Oznur Bal, Yusuf Acikgoz, Birol Yildiz, Fahriye T Kos, Efnan Algin, Mutlu Dogan

J Cancer Res Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine-associated digital necrosis in metastatic breast cancer.
Alper Türkel, Mustafa Özdemir, Aziz Kurtuluş, Mutlu Doğan

J Oncol Pharm Pract· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIPEC in Ovarian Cancer: When and to Whom?
Ozturk Ates, Bulent Aksel, Mehmet Hadi Akkus, Irem Oner, Cemil Yuksel, Mutlu Dogan

J Coll Physicians Surg Pak· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the serum level of survivin, an antiapoptotic protein, a potential predictive and prognostic biomarker in metastatic pancreatic cancer?
Nebi Serkan Demirci, Eyyüp Çavdar, Gokmen Umut Erdem, Engin Hatipoglu, Emir Celik, Mutlu Dogan, Erdogan Selcuk Seber

Medicine (Baltimore)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis